{
  "guideline": {
    "id": "PA166268882",
    "name": "Annotation of FDA Label for belzutifan and CYP2C19, UGT2B17",
    "objCls": "Label Annotation",
    "source": "FDA",
    "version": 11,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166268882",
    "relatedChemicals": [
      {
        "id": "PA166268761",
        "name": "belzutifan",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA124",
        "name": "cytochrome P450 family 2 subfamily C member 19",
        "symbol": "CYP2C19"
      },
      {
        "id": "PA37189",
        "name": "UDP glucuronosyltransferase family 2 member B17",
        "symbol": "UGT2B17"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166308241",
      "name": "Recommendation Annotation PA166308241",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166268761",
          "name": "belzutifan",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452193120,
        "html": "<p>&quot;Closely monitor for adverse reactions in patients who are dual UGT2B17 and CYP2C19 poor metabolizers.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"Patients who are dual UGT2B17 and CYP2C19 poor metabolizers have higher belzutifan exposures, which may increase the incidence and severity of adverse reactions of WELIREG [belzutifan].\""
      ],
      "lookupKey": {
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166309882",
      "name": "Recommendation Annotation PA166309882",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166268761",
          "name": "belzutifan",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452208381,
        "html": "<p>&quot;Closely monitor for adverse reactions in patients who are dual UGT2B17 and CYP2C19 poor metabolizers.&quot; See label for more information.</p>\n"
      },
      "implications": [
        "\"Patients who are dual UGT2B17 and CYP2C19 poor metabolizers have higher belzutifan exposures, which may increase the incidence and severity of adverse reactions of WELIREG [belzutifan].\""
      ],
      "lookupKey": {
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product WELIREG (belzutifan), NDA215383, Merck Sharp & Dohme Corp.",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215383"
    }
  ],
  "version": "2024-03-08-14-34"
}